Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
A Manual for SUVs with Less Noteworthy Gas Mileage - 2Cheetos and Doritos to launch new versions without artificial dyes
- 3The most effective method to Alter Your Kona SUV for Greatest Solace and Comfort
- 4Nurturing Hacks: Astuteness from Experienced Mothers and Fathers
- 5Dental, Vision, and Hearing Inclusion in Senior Protection.
- A definitive Manual for Well known Fragrances
- Czech Republic's new premier: No money for Ukraine
- 10 Setting up camp Shelters That Offer Both Excellence and Isolation
- Emergent Cold LatAm opens state-of-the-art cold storage hub in Guadalajara
- When fake data is a good thing – how synthetic data trains AI to solve real problems
- They grew up with 'almond moms.' Now, they dread going home for the holidays.
- Pilot captures jaw-dropping northern lights show from 36,000 feet (photos)
- The Way to Monetary Health: Individual budget Change
- Illustrations Gained from a Crosscountry Excursion
